Evaxion Biotech Future Growth
Future criteria checks 5/6
Evaxion Biotech is forecast to grow earnings and revenue by 64.7% and 47.4% per annum respectively while EPS is expected to grow by 78.5% per annum.
Key information
64.7%
Earnings growth rate
78.5%
EPS growth rate
Biotechs earnings growth | 21.3% |
Revenue growth rate | 47.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 03 Apr 2024 |
Recent future growth updates
Recent updates
Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration
Mar 31Evaxion Biotech names Per Norlén as CEO
Oct 05Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer
Sep 21Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10
Aug 10Evaxion Biotech announces new CEO as Lars Wegner resigns
Aug 02Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?
Oct 27We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely
Jun 29Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform
Jun 03Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 64 | 31 | N/A | -16 | 2 |
12/31/2025 | 18 | -4 | N/A | -6 | 3 |
12/31/2024 | 6 | -11 | N/A | -11 | 3 |
12/31/2023 | 0 | -22 | -18 | -18 | N/A |
9/30/2023 | N/A | -24 | -22 | -22 | N/A |
6/30/2023 | N/A | -25 | -24 | -24 | N/A |
3/31/2023 | N/A | -24 | N/A | N/A | N/A |
12/31/2022 | N/A | -23 | -26 | -26 | N/A |
9/30/2022 | N/A | -25 | -25 | -24 | N/A |
6/30/2022 | N/A | -24 | -25 | -24 | N/A |
3/31/2022 | N/A | -26 | -27 | -26 | N/A |
12/31/2021 | N/A | -25 | -23 | -22 | N/A |
9/30/2021 | N/A | -20 | -23 | -22 | N/A |
6/30/2021 | N/A | -19 | -20 | -19 | N/A |
3/31/2021 | N/A | -16 | -14 | -14 | N/A |
12/31/2020 | N/A | -15 | -13 | -12 | N/A |
9/30/2020 | N/A | -14 | -10 | -10 | N/A |
12/31/2019 | N/A | -11 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EVAX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: EVAX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EVAX is expected to become profitable in the next 3 years.
Revenue vs Market: EVAX's revenue (47.4% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: EVAX's revenue (47.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EVAX's Return on Equity is forecast to be high in 3 years time